Primary Biliary Cholangitis (PBC) Treatment Market to Reach USD 2.72 Billion by 2033, Driven by Next-Generation FXR Agonists & Immunomodulators | DataM Intelligence
Comunicato Precedente
Comunicato Successivo
Market Growth Drivers: Growth Trends Shaping the PBC Landscape
DataM Intelligence highlights multiple measurable factors accelerating market growth:
These metrics underscore a shift toward biomarker-driven, receptor-targeted therapies that deliver clinically meaningful liver function improvement.
Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=primary-biliary-cholangitis-treatment-market
Market Segmentation Analysis
By Drug Type
The market includes Obeticholic Acid, Seladelpar, Elafibranor, Ursodeoxycholic Acid (UDCA), and Other Emerging Therapies.
By Age Group
By 2033, the geriatric treatment segment is expected to cross USD 1.1 billion, growing in line with global demographic shifts.
Download PDF Brochure: https://www.datamintelligence.com/download-sample/primary-biliary-cholangitis-treatment-market
Browse in-depth TOC on "Primary Biliary Cholangitis Treatment Market"
70 – Tables
66 – Figures
195 – Pages
Regional Insights
United States
The U.S. accounted for approximately 46% of global market revenue (USD 610 million in 2024) and is projected to surpass USD 1.25 billion by 2033 at 8% CAGR.
Key quantitative drivers:
Japan
Japan's PBC treatment market reached USD 98 million in 2024, expected to rise to USD 192 million by 2033 at 7.6% CAGR.
Key growth indicators:
Competitive Landscape
According to DataM Intelligence, the market is moderately competitive with a blend of innovator companies, generics manufacturers, and emerging clinical-stage biotechs.
Key Players:
Pharmaceuticals, Inc. | Gilead Sciences, Inc. | Ipsen Biopharmaceuticals, Inc. | Teva Pharmaceutical
USA, Inc. | Glenmark Pharmaceuticals Inc. | AbbVie Inc. | Aden Healthcare | Zydus Therapeutics Inc. | COUR Pharmaceuticals | Kowa Company, Ltd. | Mirum Pharma | Parvus Therapeutics Inc. | GSK plc | Strides Pharma Science Limited | Calliditas Therapeutics AB
Key Highlights:
Collectively, top global players represent over 68% of total PBC treatment revenue, reflecting strong clinical investments and regulatory momentum.
Request for Customized Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/primary-biliary-cholangitis-treatment-market
Market Outlook & Strategic Opportunities
Conclusion
The Primary Biliary Cholangitis Treatment Market is entering a new therapeutic era as next-generation FXR agonists, PPAR modulators, and immunomodulatory therapies reshape disease management. Growing from USD 1.33 billion in 2024 to USD 2.72 billion by 2033, the sector is expanding at a steady 7.8% CAGR.
According to DataM Intelligence, pharmaceutical innovators focusing on targeted, liver-specific mechanisms and long-term safety profiles will drive the next decade of clinical and commercial breakthroughs in PBC treatment.
Related Report:
About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn, and Facebook.
Contact:
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo
View original content:https://www.prnewswire.co.uk/news-releases/primary-biliary-cholangitis-pbc-treatment-market-to-reach-usd-2-72-billion-by-2033--driven-by-next-generation-fxr-agonists--immunomodulators--datam-intelligence-302618302.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
